Literature DB >> 27134804

Oncology Section EDGE Task Force on Prostate Cancer: A Systematic Review of Outcome Measures for Health-Related Quality of Life.

Shana Harrington1, Jeannette Lee2, Genevieve Colon3, Meryl Alappattu4.   

Abstract

BACKGROUND: Health-related quality of life (HRQOL) is multidimensional and subjective, encompassing occupational and physical function, psychological state, social interaction, and somatic sensation. Because of the wide scope of HRQOL and its implications for the medical management of prostate cancer survivors, clinicians and researchers need to know the most reliable and valid measures currently available for addressing this clinical construct in men diagnosed with prostate cancer.
PURPOSE: To identify and evaluate patient-reported outcome measures used to assess HRQOL in men diagnosed with prostate cancer and make recommendations for the use of these patient-reported outcome measures in both the research and clinic settings.
METHODS: The literature was systematically reviewed for patient-reported outcome measures used in peer-reviewed, published research to assess HRQOL in men diagnosed with prostate cancer. The goals were to examine the psychometric properties of commonly used HRQOL measures in order to determine their clinical utility.
RESULTS: The following patient-reported outcome measures are highly recommended by the Task Force to assess HRQOL in men diagnosed with prostate cancer: EORTC QLQ-P25 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate 25), EPIC (Expanded Prostate Cancer Index Composite), FACT-P (Functional Assessment of Cancer Therapy-Prostate), UCLA-PCI (UCLA-Prostate Cancer Index), EORTC QLQ-C30 (EORTC Quality of Life Questionnaire-Cancer 30), FACT-G (Functional Assessment of Cancer Therapy-General), and SF (Short-Form) 36, 12, and 8.
CONCLUSIONS: A variety of patient-reported outcome measures have been reported in the literature to assess HRQOL in men diagnosed with prostate cancer. Seven measures were found to have satisfactory psychometric properties, as well as good clinical utility, and are recommended for use by the researchers on this Task Force.

Entities:  

Keywords:  outcome measure; prostate cancer; quality of life

Year:  2016        PMID: 27134804      PMCID: PMC4851243     

Source DB:  PubMed          Journal:  Rehabil Oncol        ISSN: 2381-2427


  46 in total

1.  The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.

Authors:  M A Sprangers; M Groenvold; J I Arraras; J Franklin; A te Velde; M Muller; L Franzini; A Williams; H C de Haes; P Hopwood; A Cull; N K Aaronson
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

2.  Quality of life after treatment for localized prostate cancer: differences based on treatment modality.

Authors:  J W Davis; D A Kuban; D F Lynch; P F Schellhammer
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

3.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.

Authors:  J T Wei; R L Dunn; M S Litwin; H M Sandler; M G Sanda
Journal:  Urology       Date:  2000-12-20       Impact factor: 2.649

4.  Cross-cultural validation of the UCLA prostate cancer index.

Authors:  Pierre I Karakiewicz; Michael W Kattan; Simon Tanguay; Mostafa M Elhilali; Michel Bazinet; Peter T Scardino; Armen G Aprikian
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

5.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

Authors:  P Esper; F Mo; G Chodak; M Sinner; D Cella; K J Pienta
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

6.  Responsiveness of disease-specific and generic utility instruments in prostate cancer patients.

Authors:  Murray Krahn; Karen E Bremner; George Tomlinson; Paul Ritvo; Jane Irvine; Gary Naglie
Journal:  Qual Life Res       Date:  2006-11-08       Impact factor: 4.147

7.  Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.

Authors:  Thomas Wahlgren; Yvonne Brandberg; Lars Häggarth; Magnus Hellström; Sten Nilsson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-09-01       Impact factor: 7.038

8.  Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales.

Authors:  David Cella; David T Eton; Jin-Shei Lai; Amy H Peterman; Douglas E Merkel
Journal:  J Pain Symptom Manage       Date:  2002-12       Impact factor: 3.612

Review 9.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

10.  Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up.

Authors:  Montse Ferrer; Ferran Guedea; José Francisco Suárez; Belén de Paula; Víctor Macías; Alfonso Mariño; Asunción Hervás; Ismael Herruzo; María José Ortiz; Javier Ponce de León; Gemma Sancho; Ana Boladeras; Adriana Ayala; Jordi Craven-Bratle; Mónica Ávila; Oriol Cunillera; Yolanda Pardo; Jordi Alonso; Ferran Aguiló
Journal:  Radiother Oncol       Date:  2013-07-09       Impact factor: 6.280

View more
  5 in total

1.  Assessment of acute bowel function after radiotherapy for prostate cancer: Is it accurate enough?

Authors:  M Bonet; L Cayetano; M Núñez; E Jovell-Fernández; A Aguilar; Y Ribas
Journal:  Clin Transl Oncol       Date:  2017-09-12       Impact factor: 3.405

2.  Muscle wasting assessment tools for prostate cancer.

Authors:  Alan Espinosa-Marrón; Aquiles Rubio-Blancas; Christian Aníbal Quiñones-Capistran; Anais Camacho-Zamora; Itzel Salcedo-Grajales; Ana Paula Bravo-García; Maria T Bourlon; Ricardo A Castillejos-Molina; Julie-Alexia Dias; María Del Pilar Milke-García
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.379

3.  Artificial intelligence supporting cancer patients across Europe-The ASCAPE project.

Authors:  Lazaros Tzelves; Ioannis Manolitsis; Ioannis Varkarakis; Mirjana Ivanovic; Miltiadis Kokkonidis; Cristina Sabater Useros; Thanos Kosmidis; Montserrat Muñoz; Imma Grau; Manos Athanatos; Anamaria Vizitiu; Konstantinos Lampropoulos; Tzortzia Koutsouri; Dimitra Stefanatou; Konstantinos Perrakis; Christina Stratigaki; Serge Autexier; Paris Kosmidis; Antonis Valachis
Journal:  PLoS One       Date:  2022-04-21       Impact factor: 3.240

4.  Stromal reactivity differentially drives tumour cell evolution and prostate cancer progression.

Authors:  Simon W Hayward; Gustavo Ayala; Alexander R A Anderson; Ziv Frankenstein; David Basanta; Omar E Franco; Yan Gao; Rodrigo A Javier; Douglas W Strand; MinJae Lee
Journal:  Nat Ecol Evol       Date:  2020-05-11       Impact factor: 19.100

5.  The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.

Authors:  Martin H Umbehr; Lucas M Bachmann; Cedric Poyet; Peter Hammerer; Johann Steurer; Milo A Puhan; Anja Frei
Journal:  Health Qual Life Outcomes       Date:  2018-02-20       Impact factor: 3.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.